24/7 Market News Snapshot 01 October, 2024 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

October 1, 2024

DENVER, Colo., 01 October, 2024 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (SLXN) is experiencing a significant surge in pre-market trading, with stock prices soaring by 41.47% to $0.743, following a close of $0.525. This robust activity is underscored by a trading volume of 6.06 million shares, reflecting increased investor interest in the biotech firm. Analysts are attentive to this momentum, potentially signifying a breakout opportunity for those looking to invest in the stock.

Concurrently, Silexion has announced promising advancements in its RNA interference (RNAi) therapy pipeline, particularly regarding SIL-204, a next-generation small interfering RNA (siRNA) candidate aimed at KRAS-driven cancers. Recent preclinical findings reveal that SIL-204, utilizing a novel microparticle formulation, effectively inhibits the proliferation of pancreatic tumor cells that exhibit the KRAS G12D mutation, a common variant associated with pancreatic cancer.

This innovative therapy demonstrates significant anti-tumor efficacy with a single dose of the advanced formulation, contrasting with older methods that required daily injections. Histopathological evaluations have shown pronounced tumor necrosis, further validating the therapy’s potential to significantly diminish tumor size.

The optimization from traditional PLGA depot rods to a refined PLGA microparticle format has enhanced SIL-204’s release characteristics, increasing its therapeutic effectiveness. As Silexion moves forward, it plans to initiate toxicology studies shortly, with the aim of starting Phase 2/3 clinical trials by early 2026. The primary focus will be on locally advanced pancreatic cancer, notorious for its high mortality rates, with future research contemplating SIL-204’s efficacy in addressing colorectal cancer as well.

As an emerging entity in the oncology biotechnology sector, Silexion Therapeutics is dedicated to advancing RNAi therapies, demonstrating a commitment to improving patient outcomes in challenging cancer types. Further updates are anticipated as the company progresses in its mission to deliver innovative cancer treatments.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.